SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SRDX - SurModics - Biotech IPO
SRDX 26.95-1.6%3:59 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Will Preska who started this subject10/27/2003 4:36:09 PM
From: Lance Bredvold   of 84
 
Amersham selected for EPA CodeLink Custom Bioarrays:
Motorola developed this technology as I understand it, sold it to Amersham a few years ago and just in the last few weeks GE (US) has made an offer to purchase Amersham. Thanks to tinsnipson on the Yahoo thread for monitoring this (second largest?) customer of SRDX.

amersham.co.uk

United States Environmental Protection Agency selects Amersham Biosciences' CodeLink Custom Bioarrays for Gene Expression Profiling

The United States Environmental Protection Agency (EPA) has selected CodeLink™ Custom Bioarrays from Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM), to perform gene expression experiments aimed at identifying biomarkers to assess aquatic toxicity.

The new CodeLink Custom Bioarray service will allow the EPA to rapidly design unique fathead minnow bioarrays using the established "Six Sigma" manufacturing processes used for all CodeLink products. Using these Custom Bioarrays, the EPA will be able to quickly screen their selected genes with the highest degree of accuracy and reproducibility to determine the best set of biological indicators to use for identifying contaminants in the aquatic environment.

The EPA will provide gene sequences from the fathead minnow (Pimephales promelas), a standard animal model for aquatic toxicology studies, which Amersham Biosciences will use to create customized gene microarrays. According to Drs. David Lattier and Ann Miracle, co investigators at the EPA, customized gene microarrays will greatly accelerate the ability to develop bioindicators for toxicity in aquatic ecosystems. The custom-designed DNA bioarrays will enable rapid, accurate, and high throughput screening for molecular markers and ultimately provide a valuable tool for assessing risks to the nation's water resources.

"We are very honoured to work with the EPA to develop this important water toxicity tool," comments Sam Raha, Vice President of CodeLink at Amersham Biosciences. "This collaborative effort with the EPA marks the official launch of our CodeLink Custom Bioarray Service, which offers customers access to proprietary CodeLink microarray technology together with the flexibility of customizing the content and design of the arrays."

As part of the CodeLink Custom Array Service, customers can have arrays made by selecting tailored subsets of human, mouse and rat CodeLink content or by specifying any content of their choice. CodeLink Bioarrays utilize patented 3-D matrix technology along with functionally validated genes to offer the most reproducible, sensitive and reliable microarrays available.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext